Drug delivery of oligonucleotides by peptides

被引:85
作者
Lochmann, D
Jauk, E
Zimmer, A
机构
[1] Karl Franzens Univ Graz, Inst Pharmaceut Sci, Dept Pharmaceut Technol, A-8010 Graz, Austria
[2] Goethe Univ Frankfurt, Inst Pharmaceut Technol, D-6000 Frankfurt, Germany
关键词
oligonucleotides; drug delivery; fusogenic peptides; poly-L-lysine; protamine; NLS;
D O I
10.1016/j.ejpb.2004.03.031
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Oligonucleotides are promising tools for in vitro studies where specific downregulation of proteins is required. In addition, antisense oligonucleotides have been studied in vivo and have entered clinical trials as new chemical entities with various therapeutic targets such as antiviral drugs or for tumour treatments. The formulation of these substances were widely studied in the past. With this review we will focus on peptides used as drug delivery vehicles for oligonucleotides. Different strategies are summarised. Cationically charged peptides from different origins were used e.g. as cellular penetration enhancers or nuclear localisation tool. Examples are given for Poly-L-lysine alone or in combination with receptor specific targeting ligands such as asialoglycoprotein, galactose, growth factors or transferrin. Another large group of peptides are those with membrane translocating properties. Fusogenic peptides rich in lysine or arginine are reviewed. They have been used for DNA complexation and condensation to form transport vehicles. Some of them, additionally, have so called nuclear localisation proper-ties. Here, DNA sequences, which facilitate intracellular trafficking of macromolecules to the nucleus were explored. Summarizing the present literature, peptides are interesting pharmaceutical excipients and it seems to be feasible to combine the specific properties of peptides to improve drug delivery devices for oligonucleotides in the future. (C) 2004 Elsevier B.V. All rights reserved.
引用
收藏
页码:237 / 251
页数:15
相关论文
共 179 条
[1]   The delivery of antisense therapeutics [J].
Akhtar, S ;
Hughes, MD ;
Khan, A ;
Bibby, M ;
Hussain, M ;
Nawaz, Q ;
Double, J ;
Sayyed, P .
ADVANCED DRUG DELIVERY REVIEWS, 2000, 44 (01) :3-21
[2]   DOWN-REGULATION OF AMYLOID PRECURSOR PROTEIN INHIBITS NEURITE OUTGROWTH IN-VITRO [J].
ALLINQUANT, B ;
HANTRAYE, P ;
MAILLEUX, P ;
MOYA, K ;
BOUILLOT, C ;
PROCHIANTZ, A .
JOURNAL OF CELL BIOLOGY, 1995, 128 (05) :919-927
[3]  
ANDO T, 1973, PROTAMINES ISOLATION, V1
[4]   Peptide-oligonucleotide phosphorothioate conjugates with membrane translocation and nuclear localization properties [J].
Antopolsky, M ;
Azhayeva, E ;
Tengvall, U ;
Auriola, S ;
Jääskeläinen, I ;
Rönkkö, S ;
Honkakoski, P ;
Urtti, A ;
Lönnberg, H ;
Azhayev, A .
BIOCONJUGATE CHEMISTRY, 1999, 10 (04) :598-606
[5]   Molecular medicine - Antisense oligonucleotide therapy [J].
Askari, FK ;
McDonnell, WM .
NEW ENGLAND JOURNAL OF MEDICINE, 1996, 334 (05) :316-318
[6]   Conjugates of antisense oligonucleotides with the Tat and antennapedia cell-penetrating peptides: Effects on cellular uptake, binding to target sequences, and biologic actions [J].
Astriab-Fisher, A ;
Sergueev, D ;
Fisher, M ;
Shaw, BR ;
Juliano, RL .
PHARMACEUTICAL RESEARCH, 2002, 19 (06) :744-754
[7]  
ASTRIABFISHER A, 2002, J BIOL CHEM, V277, P22980
[8]   Interaction of the third helix of Antennapedia homeodomain and a phospholipid monolayer, studied by ellipsometry and PM-IRRAS at the air-water interface [J].
Bellet-Amalric, E ;
Blaudez, D ;
Desbat, B ;
Graner, F ;
Gauthier, F ;
Renault, A .
BIOCHIMICA ET BIOPHYSICA ACTA-BIOMEMBRANES, 2000, 1467 (01) :131-143
[9]  
Boulikas T, 1997, INT J ONCOL, V10, P317
[10]   In vivo nuclear delivery of oligonucleotides via hybridizing bifunctional peptides [J].
Brandén, LJ ;
Christensson, B ;
Smith, CIE .
GENE THERAPY, 2001, 8 (01) :84-87